肝癌患者肝移植前行TACE治疗的效果及其对肝移植预后的影响

目的 探讨肝癌患者肝移植前行肝动脉介入栓塞化疗(TACE)的效果及其对肝移植预后的影响.方法 共有67例肝癌患者在施行肝移植前接受了TACE治疗,其中男性52例,女性15例,年龄34～67岁,平均48岁;符合米兰标准者61例,超出米兰标准6例.肝移植术式采用经典原位肝移植62例,背驮式肝移植5例.术后免疫抑制方案采用他克莫司(或环孢素A、或西罗莫司)+吗替麦考酚酯+糖皮质激素.根据术后病肝的组织病理学检查结果,判断TACE的治疗效果,并比较TACE治疗效果不同者间术后1年和2年肿瘤复发率及存活率.结果 肿瘤结节坏死50%以上者有50例,其中新生肿瘤结节者2例,经TACE治疗后肿瘤结节坏死率为73.77%.肿瘤结节坏死50%以下者有17例,其中新生肿瘤结节者7例.TACE治疗效果良好和无新生肿瘤结节者48例,其移植后1年和2年肿瘤复发率分别为2.08%(1/48)和6.25%(3/48),存活率分别为97.92%(47/48)和95.83%(46/48);TACE治疗较差且发现新生肿瘤结节者19例,其移植后1年和2年肿瘤复发率分别为36.84%(7/19),和57.89%(11/19),存活率分别为73.68%(14/19)和47.37%(9/19),二组各数据相比较,差异均有统计学意义(P＜0.05).结论 TACE可以较好的局部控制肝癌,但对于术前未发现的肿瘤结节影响有限.移植前接受TACE治疗效果较好者,其预后也较好,TACE治疗的效果可以作为判断肝移植预后的一个指标.

The efficacy of preoperative transcatheter artery chemoembolization correlates with outcome after orthotopic liver transplantation in patients with hepatocellular carcinoma

Objective To investigate the efficacy of preoperative transcatheter artery chemoembolization (TACE) correlates with outcome after orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC). Methods Sixty-seven patients with HCC underwent TACE before OLT. In all the patients, there were 52 males and 15 females with age ranging from 34 to 67 years old (average 48). Sixty-one patients met the Milan' standard, and 6 patients exceeded Milan' standard. Classic OLT was done in 62 patients and pigyback liver transplantation was done in 5 patients. Immunosuppression regimen after operation included Tacrolimus (or Ciclosporin,Sirolimus), mycophynolate, steroid hormone. The efficacy of TACE was assessed according to histological findings after OLT. Tumor recurrence rate of 1-and 2-year tumor recurrence rate, and 1-and 2-year survival rate in different groups with different responses to preoperative TACE were compared. Results Tumor necrosis rate was greater than 50% in 50 patients and new tumor nodi occurred in 2 patients. Tumor necrosis rate after TACE was 73. 77%. Tumor necrosis rate was less than 50% in 17 patients and new tumor nodi occurred in 7 patients. Forty-eight patients had satisfactory efficacy after TACE and no new tumor nodi occurred, 1-and 2-year tumor recurrence rate was 2. 08/ (1/48) and 6. 25% (3/48) respectively, and 1- and 2-year survival rate was 97. 92% (47/48) and 95. 83% (46/48) respectively. Nineteen patients had worse efficacy after TACE and new nodi occurred, 1- and 2-year tumor recurrence rate was 36. 84% (7/19) and 57. 89% (11/19), and 1-and 2-year survival rate was 73.68% (14/19) and 47. 37% (9/19) respectively. There were statistically significant difference between the two groups (P＜0.05). Conclusion TACE provides good local control in preoperatively diagnosed HCC, but its impact is limited in lesions not detected preoperatively. Patients with satisfactory efficacy after TACE before OLT had a good prognosis. The response to preoperative TACE may predict long-term outcome after LT.